MENTALHEALTH.INFOLABMED.COM - WASHINGTON, D.C. – October 19, 2026 – A significant executive order signed today by President Donald J. Trump aims to elevate the focus on women's health research and outcomes across the United States. Championed by First Lady Melania Trump, the order mandates the establishment of a new Women's Health Division within the National Institutes of Health (NIH), a move designed to accelerate scientific discovery and improve health for American women and girls.
The directive requires the Department of Health and Human Services (HHS), through the NIH, to create this dedicated division within 90 days.
This new entity will collaborate with the existing NIH Office of Research on Women’s Health.
Its primary objectives include advancing research into conditions that specifically or disproportionately impact women, enhancing accountability in federally funded research initiatives, and expediting the translation of scientific findings into actionable prevention strategies, diagnostic tools, treatments, and clinical care practices.
White House Task Force to Coordinate Federal Efforts
In tandem with the NIH division, the executive order establishes the inaugural White House Women's Health Task Force.
This task force will be co-chaired by HHS Secretary Robert F.
Kennedy, Jr. and White House Chief of Staff Susie Wiles.
Its mandate is to streamline and coordinate federal efforts aimed at enhancing women's health throughout all life stages, from infancy and adolescence, through reproductive years, midlife, menopause, and into healthy aging.
“President Trump is transforming how our nation approaches women’s health by making it a priority across every stage of life,” stated HHS Secretary Robert F.
Kennedy, Jr.
He emphasized the instrumental role of First Lady Melania Trump’s leadership in realizing the executive order and acknowledged the strong support from co-chair Susie Wiles.
Secretary Kennedy further remarked, “For generations, women have faced unanswered questions about conditions that uniquely or disproportionately affect them.
This new NIH division will confront those questions with gold-standard science, accelerate research into prevention and treatment, and turn medical discoveries into better care for women and girls across America.”
Scope of Research and Clinical Impact
The forthcoming NIH Women’s Health Division is slated to conduct research across a broad spectrum of conditions.
These include, but are not limited to, cardiovascular disease, various cancers, autoimmune and inflammatory disorders, chronic pain, endometriosis, fibroids, polyendocrine metabolic ovary syndrome (PMOS), infertility, maternal health, menopause-related issues, Alzheimer’s disease, and osteoporosis.
The division's work will involve intensified scientific review of understudied women's health concerns, promotion of advanced research technologies and personalized medicine, strengthening of interdisciplinary research collaborations, and a deeper understanding of sex-specific health outcomes.
It will also focus on increasing the inclusion of women and girls in clinical trials, reinforcing NIH's requirement to consider sex as a biological variable, and ensuring that scientific breakthroughs are effectively integrated into clinical practice.
NIH Director Jay Bhattacharya commented on the significance of this initiative, stating, “Women deserve strong research that helps them and their doctors answer key health questions they face at every stage of life.
This new division will help close lingering evidence gaps, expand and maximize the impact of our research investments, and bring discoveries closer to patients.” Echoing this sentiment, Dr.
Erica Schwartz, Director of the Centers for Disease Control and Prevention, added, “Today, we’re ensuring women’s needs, experiences, and voices guide the care they receive at every stage of life.
This executive order will help us put proven interventions into practice, diagnose conditions earlier, expand treatment options, and prevent disease.”
Building on Previous Initiatives
This executive order signifies an expansion upon actions initiated by HHS since January 2025.
These prior efforts have aimed to shift women's healthcare towards a holistic approach, emphasizing prevention, root cause analysis, rigorous scientific inquiry, and informed decision-making, moving away from treating conditions in isolation.
Key developments include expanded women's health research at NIH focusing on areas like midlife health and autoimmune diseases, modernization of menopause care with FDA actions on hormone replacement therapy, and the approval of two new medications for menopausal symptoms, including a generic Premarin and a non-hormonal treatment for hot flashes.
Furthermore, initiatives like the Breast Cancer Screening and Diagnostic Follow-up Initiative and the Infertility Initiative have been launched to enhance screening and analyze health data related to infertility and maternal-infant health.
The administration has also strengthened fertility and reproductive health services, proposed pathways for fertility benefits, and bolstered maternal and preventive health services, including the launch of Moms.gov and significant investment in home visiting services.
In March 2026, HHS convened the first National Conference on Women’s Health, bringing together a wide array of professionals to identify solutions for persistent gaps in research and care.
These combined efforts underscore the Trump Administration's comprehensive approach to advancing women's health across their lifespans, grounded in scientific evidence and clinical application, with the ultimate goal of empowering women and their clinicians with better information for informed healthcare decisions.
